Annals of the Rheumatic Diseases: 62 (suppl 2)

Preface

Advances in targeted therapies V (7 October, 2003)
F C Breedveld, J R Kalden, J S Smolen

Consensus statement

Updated consensus statement on biological agents for the treatment of rheumatoid arthritis and other immune mediated inflammatory diseases (May 2003) (7 October, 2003)
D E Furst, F C Breedveld, J R Kalden, J S Smolen, G R Burmester, M Dougados, P Emery, A Gibofsky, A F Kavenaugh, E C Keystone, L Klareskog, A S Russell, L B A van de Putte, M H Weisman

Clinical aspects

Imaging: do erosions heal? (7 October, 2003)
D van der Heijde, R Landewé
Comparison of the efficacy of the tumour necrosis factor α blocking agents adalimumab, etanercept, and infliximab when added to methotrexate in patients with active rheumatoid arthritis (7 October, 2003)
M C Hochberg, J K Tracy, M Hawkins-Holt, R H Flores

Innate immunity

Roles of antimicrobial peptides such as defensins in innate and adaptive immunity (7 October, 2003)
J J Oppenheim, A Biragyn, L W Kwak, D Yang
Possible targeting of G protein coupled receptors to manipulate inflammation in vivo using synthetic and natural ligands (7 October, 2003)
J F Kinsel, M V Sitkovsky

Regulation of the immune response

Actions of BAFF in B cell maturation and its effects on the development of autoimmune disease (7 October, 2003)
F Melchers

Update of IL1 and TNF blockade

British Society for Rheumatology Biologics Register (7 October, 2003)
A Silman, D Symmons, D G I Scott, I Griffiths
Survival during treatment with tumour necrosis factor blocking agents in rheumatoid arthritis (7 October, 2003)
M Flendrie, M C W Creemers, P M J Welsing, A A den Broeder, P L C M van Riel
Advances in targeted therapy: safety of biological agents (7 October, 2003)
E C Keystone
Role of tumour necrosis factor (TNF) in host defence against tuberculosis: implications for immunotherapies targeting TNF (7 October, 2003)
S Ehlers

New targets

Metalloproteinases, inflammation, and rheumatoid arthritis (7 October, 2003)
F F Mohammed, D S Smookler, R Khokha
Role of interleukin 18 in rheumatoid arthritis (7 October, 2003)
F Y Liew, X-Q Wei, I B McInnes
New strategies to control inflammatory synovitis: interleukin 15 and beyond (7 October, 2003)
I B McInnes, J A Gracie, M Harnett, W Harnett, F Y Liew
B cell therapy for rheumatoid arthritis: the rituximab (anti-CD20) experience (7 October, 2003)
T Shaw, J Quan, M C Totoritis
Angiogenesis as a target in rheumatoid arthritis (7 October, 2003)
A E Koch
Interleukin 6 receptor as a target for the treatment of rheumatoid arthritis (7 October, 2003)
E Choy
α₄ Integrin blockade in inflammatory bowel disease
(7 October, 2003)
S Ghosh
Cartilage morphogenetic proteins: role in joint development, homoeostasis, and regeneration (7 October, 2003)
A H Reddi
Therapeutic targets in osteoarthritis: from today to tomorrow with new imaging technology (7 October, 2003)
J-P Pelletier, J Martel-Pelletier

Signal transduction in mesenchymal cells

Signalling in osteoclasts and the role of Fos/AP1 proteins (7 October, 2003)
E F Wagner, K Matsuo
Signal transduction networks in rheumatoid arthritis (7 October, 2003)
D Hammaker, S Sweeney, G S Firestein

From animal models to new treatments in RA

Prospects for the development of small molecular weight compounds to replace anti-tumour necrosis factor biological agents (7 October, 2003)
B Foxwell, E Andreakos, F Brennan, M Feldmann, C Smith, M Conron
Rheumatoid arthritis in 2003: where are we now with treatment? (7 October, 2003)
M E Weinblatt

Main menu

Table of contents

November 2003 - Volume 62 - suppl 2

Advances in targeted therapies V

Preface

Consensus statement

Clinical aspects

Innate immunity

Regulation of the immune response

Update of IL1 and TNF blockade

New targets

Signal transduction in mesenchymal cells

From animal models to new treatments in RA

Issue Information

Log in using your username and password

Main menu

Log in using your username and password

You are here

Table of contents

November 2003 - Volume 62 - suppl 2

Advances in targeted therapies V

Preface

Consensus statement

Clinical aspects

Innate immunity

Regulation of the immune response

Update of IL1 and TNF blockade

New targets

Signal transduction in mesenchymal cells

From animal models to new treatments in RA

Issue Information